Navigation Links
Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
Date:9/23/2009

b>About MDV3100

MDV3100 is an investigational therapy in clinical development for the treatment of advanced prostate cancer. The first triple-acting, oral anti-androgen, MDV3100 has been shown in preclinical studies to provide more compIete suppression of the androgen receptor pathway than bicalutamide, the most commonly used anti-androgen. MDV3100 slows growth and induces cell death in bicalutamide-resistant cancers via three complementary actions - MDV3100 blocks testosterone binding to the androgen receptor, impedes movement of the androgen receptor to the nucleus of prostate cancer cells (nuclear translocation), and inhibits binding to DNA. Preclinical data published in Science earlier this year demonstrated that MDV3100 is superior to bicalutamide in each of these three actions.

Medivation previously announced interim safety and efficacy results from an ongoing Phase 1-2 clinical trial of MDV3100. The interim results showed that MDV3100 was associated with anti-tumor activity in patients who had become resistant to bicalutamide or other standard anti-androgen treatments, including both patients who had failed prior chemotherapy and patients who were chemotherapy naive. Anti-tumor activity was demonstrated by reductions in prostate-specific antigen levels, improvement or stabilization in tumors that had spread to soft tissue or bone, and a decrease in circulating tumor cells, which has been associated in published literature with improved survival in patients with castration-resistant prostate cancer. MDV3100 was generally well tolerated in this trial at doses up to and including 240 mg/day, with fatigue being the most frequently reported adverse event.

About Prostate Cancer

According to the American Cancer Society, prostate cancer is the most common non-skin cancer among men in the United States. More than 2 million American men have prostate cancer, and it is the second leading cau
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
2. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
3. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
4. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
5. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
6. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
7. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
8. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
9. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
10. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
11. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... N.Y., Dec. 16 BioSpecifics Technologies Corp. ... first in class collagenase-based products, today announced top-line ... clinical trial of XIAFLEX(TM) for the treatment of ... presence of inelastic collagen on the shaft of ... make sexual intercourse difficult or impossible in advanced ...
(Date:12/16/2009)... 16 Vivakor, Inc. (OTC Bulletin ... agreement with Baker Consulting out of Walnut ... Group, Inc. out of South Florida. ... to assist with business development, financing and ... acquisition strategy. Specifically, Baker Consulting is exploring ...
(Date:12/16/2009)... -- Naurex Inc., a new clinical stage company ... disorders based on its novel GFPA NMDA receptor ... Phase I clinical trial of its lead compound ... in the study. GLYX-13, a glycine site ... NMDA receptor, is initially being developed as a ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4Vivakor Signs Business Development Agreement With Baker Consulting 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3Hoarseness predominates in vocal health issues for inner city children 58831 1Designing drugs and their antidotes together improves patient care 58829 1Designing drugs and their antidotes together improves patient care 58829 2Designing drugs and their antidotes together improves patient care 58829 3Global death toll 3A 1 million premature babies every year 58827 1Global death toll 3A 1 million premature babies every year 58827 2Global death toll 3A 1 million premature babies every year 58827 3Global death toll 3A 1 million premature babies every year 58827 4
... - ZIOPHARM Oncology, Inc.,(NASDAQ: ZIOP) announced today that ... the C.E. Unterberg, Towbin,Emerging Growth Opportunities Conference on ... the Mandarin Oriental Hotel, New York. Dr. Lewis,will ... update on its,clinical development programs., The presentation will ...
... -- Micromet,Inc. , a biopharmaceutical company focusing on ... inflammatory,and autoimmune diseases, today announced that Dr. Christian ... will,present at the 3rd Annual C.E. Unterberg, Towbin ... 12, 2007 at 10:00am,eastern. , A webcast of ...
Other Medicine Technology:ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth,Opportunities Conference 2Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin,Emerging Growth Conference 2
(Date:12/16/2009)... Offers Planet-Friendly Organics, Solar-Powered Manufacturing and Sustainable Packaging at an ... ... Los Angeles, CA (PRWEB) December 16, 2009 -- Actively healthy ... in all natural skin care for their children as ... children featuring the beloved artwork of The Very Hungry Caterpillar ...
(Date:12/16/2009)... direct link has been found, , , WEDNESDAY, Dec. 16 ... commonly linked to food poisoning and the stomach pain ... cause of some urinary tract infections. , Researchers have ... from stores and restaurants and in women with the ... were transmitted directly to the women through the food ...
(Date:12/16/2009)... promote Massachusetts companies through annual marketing campaign , ... ... BioSpace unveiled the 2010 Genetown™ Hotbed Campaign as ... , ,Genetown is sponsored by MassBio and showcases ... The campaign places each entity’s brand on an electronic ...
(Date:12/16/2009)... government report shows, , , WEDNESDAY, Dec. 16 (HealthDay News) ... reached almost 78 years, a record high, federal health ... can expect to live to 80.4 years on average ... from the U.S. Centers for Disease Control and Prevention. ... live longer than their parents, life expectancy in the ...
(Date:12/16/2009)... Dec. 16 Medical travel facilitator Companion ... in Puerto Rico into its network of international ... lower than those at mainland U.S. facilities. ,, ... medical travel assistance and preferred pricing for its ... treatment at either HIMA San Pablo Bayamon or ...
Breaking Medicine News(10 mins):Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 2Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 3Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 4Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 5Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 2Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 3Health News:Thriving Bioscience Region Leaves Its Mark 2Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3Health News:Hospitals in Puerto Rico Join Companion Global Healthcare's Network 2
... Ill., Feb. 25 Omron Healthcare, Inc. ... chief operating officer. With,an extensive background in ... sales and profit growth in their mainstay ... and professional medical. Kondraske,s experience as a ...
... CHARLOTTESVILLE, Va., Feb. 25 Meddius, an ... will,provide integration technology and professional services to ... control system,which provides hospitals with a Web-based, ... healthcare associated infections (HAIs). The announcement,was made ...
... chain management system enhanced to support multifaceted hospital, environments; ... ... ORLANDO, Fla., Feb. 25 HIMSS ,08 -- ... system solutions to acute,healthcare facilities, today introduced its OptiFlex(TM) ...
... Platform helps hospitals automate charity care, ... Form 990, CHICAGO, Feb. 25 The ... the process that assists,hospitals in determining whether a ... addresses many of Ohio Attorney General Marc Dann,s,concerns ...
... PORTLAND, Ore., Feb. 25 The Food ... cancer of the colon and,lungs. In off-label use, ... that,s currently used by some doctors to treat ... neck, pancreatic, ovarian,and hepatocellular., Some ophthalmologists are ...
... According to leading weight loss,expert, Dr. Kent Sasse, ... actually cause more weight gain. Insulin, the primary,treatment for ... patients,in part because insulin acts on the fat storage ... these fats., Diabetes mellitus is one of the ...
Other Medicine News:Health News:Omron Healthcare Names New Chief Operating Officer Bob Kondraske 2Health News:Meddius Signs Agreement to Deliver an Integration Platform for Premier's SafetySurveillor(TM) 2Health News:Hospital Environments Increase Staff Efficiency and Patient Safety With Omnicell OptiFlex(TM) SS 9.0 2Health News:Hospital Environments Increase Staff Efficiency and Patient Safety With Omnicell OptiFlex(TM) SS 9.0 3Health News:TransUnion Addresses Ohio Attorney General's Concerns Surrounding Non-Profit Tax-Exempt Status 2Health News:TransUnion Addresses Ohio Attorney General's Concerns Surrounding Non-Profit Tax-Exempt Status 3Health News:Off-Label Avastin Use for Wet Macular Degeneration 2Health News:Off-Label Avastin Use for Wet Macular Degeneration 3Health News:Cure Diabetes with Weight Loss, Not Drugs, Expert Says 2
Histopathology Reference Laboratory provides a full range of histology services, encompassing routine and specialized grossing, processing, embedding, microtomy, routine and special staining and cove...
PhenoPath Laboratories provides screening, diagnostic, and prognostic testing services to hospitals, physician offices, surgery centers, biopharmaceutical companies and research institutions nationwi...
Headquartered in Burlington, North Carolina, LabCorp has more than 23,500 employees and offers more than 4,400 clinical tests ranging from routine blood analyses to the most sophisticated molecular d...
... The Johns Hopkins University Dermatology, ... Laboratory is a federally-(Clinical Laboratory Improvement ... that began operation in 1982. Its ... quality diagnostic allergy and immunology testing ...
Medicine Products: